Characterization of Depressive Symptoms Trajectories After Breast Cancer Diagnosis in Women in France
暂无分享,去创建一个
P. Gorwood | N. Ramoz | S. Michiels | S. Dauchy | C. Coutant | A. Viari | O. Trédan | A. Di Meglio | B. Pistilli | L. Vanlemmens | S. Everhard | Anne-Laure Martin | I. Vaz-Luis | J. Havas | C. Charles | P. Cottu | G. Menvielle | A. Dumas | E. Thomas | F. Lerebours | M. Rousseau-Tsangaris | C. Lévy | C. Jouannaud | A. Bardet | A. Larive | Seyive-Yvon-Arnauld Gbenou | M. El-Mouhebb | Fabrice André | A. Merimeche | A. Mérimèche | F. André
[1] B. Levis,et al. Accuracy of the Hospital Anxiety and Depression Scale Depression subscale (HADS-D) to screen for major depression: systematic review and individual participant data meta-analysis , 2021, BMJ.
[2] J. Ferlay,et al. Cancer statistics for the year 2020: An overview , 2021, International journal of cancer.
[3] F. André,et al. UNICANCER: French prospective cohort study of treatment-related chronic toxicity in women with localised breast cancer (CANTO) , 2019, ESMO Open.
[4] B. Avau,et al. Systematic screening and assessment of psychosocial well-being and care needs of people with cancer. , 2016, The Cochrane database of systematic reviews.
[5] Melissa Matz,et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries , 2018, The Lancet.
[6] M. Hotopf,et al. Antidepressants for the treatment of depression in people with cancer. , 2023, The Cochrane database of systematic reviews.
[7] L. Grassi,et al. Depressive Spectrum Disorders in Cancer: Diagnostic Issues and Intervention. A Critical Review , 2017, Current Psychiatry Reports.
[8] B. Johansson,et al. Development of anxiety, depression and health-related quality of life in oncology patients without initial symptoms according to the Hospital Anxiety and Depression Scale – a comparative study , 2017, Acta oncologica.
[9] C. Johansen,et al. The risk of being depressed is significantly higher in cancer patients than in the general population: Prevalence and severity of depressive symptoms across major cancer types. , 2017, European journal of cancer.
[10] S. Alfonsson,et al. Socio-demographic and clinical variables associated with psychological distress 1 and 3 years after breast cancer diagnosis , 2016, Supportive Care in Cancer.
[11] M. Quinn,et al. Predictors of depression and anxiety symptom trajectories in the 24 months following diagnosis of breast or gynaecologic cancer. , 2016, Breast.
[12] B. Johansson,et al. Identification of Distress in Oncology Patients: A Comparison of the Hospital Anxiety and Depression Scale and a Thorough Clinical Assessment , 2016, Cancer nursing.
[13] R. Jack,et al. The association of mood disorders with breast cancer survival: an investigation of linked cancer registration and hospital admission data for South East England , 2015, Psycho-oncology.
[14] John J. B. Allen,et al. Depressive episodes, symptoms, and trajectories in women recently diagnosed with breast cancer , 2015, Breast Cancer Research and Treatment.
[15] N. Avis,et al. Trajectories of Depressive Symptoms Following Breast Cancer Diagnosis , 2015, Cancer Epidemiology, Biomarkers & Prevention.
[16] C. Johansen,et al. Trajectories of distress, anxiety, and depression among women with breast cancer: Looking beyond the mean , 2015, Acta oncologica.
[17] W. Linden,et al. Emotional adjustment over 1 year post-diagnosis in patients with cancer: understanding and predicting adjustment trajectories , 2015, Supportive Care in Cancer.
[18] P. Jacobsen,et al. Depressive Symptom Trajectories During and After Adjuvant Treatment for Breast Cancer , 2014, Annals of behavioral medicine : a publication of the Society of Behavioral Medicine.
[19] R. DeRubeis,et al. Screening, assessment, and care of anxiety and depressive symptoms in adults with cancer: an American Society of Clinical Oncology guideline adaptation. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] A. Carvalho,et al. Major depressive disorder in breast cancer: a critical systematic review of pharmacological and psychotherapeutic clinical trials. , 2014, Cancer treatment reviews.
[21] P. Cuijpers,et al. Prevalence of depression in cancer patients: a meta-analysis of diagnostic interviews and self-report instruments , 2013, Psycho-oncology.
[22] Anthony Fabio,et al. Group-based trajectory analysis applications for prognostic biomarker model development in severe TBI: a practical example. , 2013, Journal of neurotrauma.
[23] C. D’Este,et al. Prevalence and predictors of the short-term trajectory of anxiety and depression in the first year after a cancer diagnosis: a population-based longitudinal study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] W. Linden,et al. Anxiety and depression after cancer diagnosis: prevalence rates by cancer type, gender, and age. , 2012, Journal of affective disorders.
[25] R. Millman,et al. Accuracy of the Hospital Anxiety and Depression Scale as a screening tool in cancer patients: a systematic review and meta-analysis , 2011, Supportive Care in Cancer.
[26] J. Neuhaus,et al. Identification of distinct depressive symptom trajectories in women following surgery for breast cancer. , 2011, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.
[27] L. Castelli,et al. Fast screening of depression in cancer patients: the effectiveness of the HADS. , 2011, European journal of cancer care.
[28] Amelia M. Haviland,et al. Group-based Trajectory Modeling Extended to Account for Nonrandom Participant Attrition , 2011 .
[29] Paul Symonds,et al. Diagnostic validity of the Hospital Anxiety and Depression Scale (HADS) in cancer and palliative settings: a meta-analysis. , 2010, Journal of affective disorders.
[30] O. Luminet,et al. Cognitive and anxiety symptoms in screening for clinical depression in diabetes: a systematic examination of diagnostic performances of the HADS and BDI-SF. , 2010, Journal of affective disorders.
[31] Daniel S Nagin,et al. Group-based trajectory modeling in clinical research. , 2010, Annual review of clinical psychology.
[32] F. Bull,et al. Global physical activity questionnaire (GPAQ): nine country reliability and validity study. , 2009, Journal of physical activity & health.
[33] Tony Jung,et al. An introduction to latent class growth analysis and growth mixture modeling. , 2008 .
[34] G. Bonanno. Loss, trauma, and human resilience: have we underestimated the human capacity to thrive after extremely aversive events? , 2008, The American psychologist.
[35] K. Roeder,et al. A SAS Procedure Based on Mixture Models for Estimating Developmental Trajectories , 2001 .
[36] N. Aaronson,et al. The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] D. Osoba,et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.
[38] G. Huston. The Hospital Anxiety and Depression Scale. , 1987, The Journal of rheumatology.